Gian Camenisch

3.1k total citations
56 papers, 2.5k citations indexed

About

Gian Camenisch is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Gian Camenisch has authored 56 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 25 papers in Pharmacology and 22 papers in Molecular Biology. Recurrent topics in Gian Camenisch's work include Drug Transport and Resistance Mechanisms (30 papers), Pharmacogenetics and Drug Metabolism (20 papers) and Drug-Induced Hepatotoxicity and Protection (9 papers). Gian Camenisch is often cited by papers focused on Drug Transport and Resistance Mechanisms (30 papers), Pharmacogenetics and Drug Metabolism (20 papers) and Drug-Induced Hepatotoxicity and Protection (9 papers). Gian Camenisch collaborates with scholars based in Switzerland, United States and France. Gian Camenisch's co-authors include H. Van De Waterbeemd, Gerd Folkers, Oleg A. Raevsky, Jacques R. Chrétien, Kenichi Umehara, Jochem Alsenz, Jörg Huwyler, Birk Poller, Annett Kunze and Michel Lemaire and has published in prestigious journals such as Journal of Controlled Release, Journal of Neurochemistry and International Journal of Pharmaceutics.

In The Last Decade

Gian Camenisch

56 papers receiving 2.4k citations

Peers

Countries citing papers authored by Gian Camenisch

Since Specialization

Citations

This map shows the geographic impact of Gian Camenisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gian Camenisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gian Camenisch more than expected).

Fields of papers citing papers by Gian Camenisch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gian Camenisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gian Camenisch. The network helps show where Gian Camenisch may publish in the future.

Co-authorship network of co-authors of Gian Camenisch

This figure shows the co-authorship network connecting the top 25 collaborators of Gian Camenisch. A scholar is included among the top collaborators of Gian Camenisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gian Camenisch. Gian Camenisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms 2024 ·Archives of Toxicology ·(unknown), Raquel Rodríguez-Pérez, Birk Poller, Felix Huth, Heiko S. Schadt, Gerd A. Kullak‐Ublick, Michael Arand, Gian Camenisch	2
2	Double Trap Interface: A novel gas interface for high throughput analysis of biomedical samples by AMS 2021 ·Drug Metabolism and Pharmacokinetics ·(unknown), Simon Fahrni, (unknown), (unknown), Markus Walles, Gian Camenisch, Lukas Wacker, Hans‐Arno Synal	6
3	Examining P-gp efflux kinetics guided by the BDDCS – Rational selection of in vitro assay designs and mathematical models 2019 ·European Journal of Pharmaceutical Sciences ·(unknown), Kenichi Umehara, (unknown), Felix Huth, Hilmar Schiller, Gian Camenisch, Birk Poller	8
4	Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes 2019 ·Pulmonary Pharmacology & Therapeutics ·Birk Poller, Ralph Woessner, Avantika Barve, Hanns-Christian Tillmann, (unknown), (unknown), (unknown), Hilmar Schiller, Peter End, Gian Camenisch, H. Weiss	8
5	In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics 2017 ·European Journal of Clinical Pharmacology ·Yi Jin, (unknown), Anne Gardin, Mike Ufer, Felix Huth, Gian Camenisch	23
6	Comparison of 19F NMR and 14C Measurements for the Assessment of ADME of BYL719 (Alpelisib) in Humans 2017 ·Drug Metabolism and Disposition ·(unknown), (unknown), (unknown), Axel Meißner, Gian Camenisch	17
7	Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction 2016 ·Drug Metabolism and Personalized Therapy ·(unknown), Kenichi Umehara, Felix Huth, Hilmar Schiller, Kelly Chibale, Gian Camenisch	16
8	New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data 2016 ·European Journal of Pharmaceutical Sciences ·(unknown), Birk Poller, Kenichi Umehara, Jörg Huwyler, Gian Camenisch	13
9	Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins 2015 ·Drug Metabolism and Personalized Therapy ·Annett Kunze, Birk Poller, Jörg Huwyler, Gian Camenisch	24
10	In Vitro–In Vivo Extrapolation Method to Predict Human Renal Clearance of Drugs 2014 ·Journal of Pharmaceutical Sciences ·Annett Kunze, Jörg Huwyler, Birk Poller, Heike Gutmann, Gian Camenisch	33
11	Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite 2014 ·Xenobiotica ·Joel A. Krauser, Yi Jin, Markus Walles, Ulrike Pfaar, James Sutton, Marion Wiesmann, Daniel Graf, (unknown), (unknown), Gian Camenisch, Piet Swart	29
12	Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters 2012 ·Biochemical Pharmacology ·Annett Kunze, Jörg Huwyler, Gian Camenisch, Heike Gutmann	52
13	Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat 2011 ·Pharmaceutical Research ·Kenichi Umehara, Gian Camenisch	52
14	Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P‐Glycoprotein in the Disposition of Aliskiren 2008 ·The Journal of Clinical Pharmacology ·Sujata Vaidyanathan, Gian Camenisch, (unknown), Christine Reynolds, (unknown), Marie‐Noëlle Bizot, H. A. Dieterich, Dan Howard, William P. Dole	87
15	Modulation of the Brain Distribution of Imatinib and its Metabolites in Mice by Valspodar, Zosuquidar and Elacridar 2007 ·Pharmaceutical Research ·(unknown), Gian Camenisch, Michel Lemaire, Jean‐Michel Scherrmann	60
16	Influence of breast cancer resistance protein (Abcg2) and p‐glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec^®) across the mouse blood–brain barrier 2007 ·Journal of Neurochemistry ·(unknown), Gian Camenisch, Michel Lemaire, Jean‐Michel Scherrmann	79
17	Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier 2006 ·Drug Metabolism and Disposition ·(unknown), Gian Camenisch, Gerhard Groß, Michel Lemaire, Jean‐Michel Scherrmann	18
18	The outstanding metabolic stability of a ¹⁴C‐labeled β‐nonapeptide in rats – in vitro and in vivo pharmacokinetic studies 2002 ·Biopharmaceutics & Drug Disposition ·(unknown), B. Wirz, Alain Schweitzer, Gian Camenisch, (unknown), Gerhard Groß, Ralph Woessner, Rolf Voges, Per I. Arvidsson, Jens Frackenpohl, Dieter Seebàch	78
19	Synthesis and Evaluation of Novel Coumarin-Based Esterase-Sensitive Cyclic Prodrugs of Peptidomimetic RGD Analogs with Improved Membrane Permeability. 1999 ·Chemical and Pharmaceutical Bulletin ·Binghe Wang, Wei Wang, Gian Camenisch, (unknown), Hongjian Zhang, R. T. BORCHARDT	18
20	Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and Shape, and H-Bonding Descriptors 1998 ·Journal of drug targeting ·H. Van De Waterbeemd, Gian Camenisch, Gerd Folkers, Jacques R. Chrétien, Oleg A. Raevsky	463

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact